Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW’s FY2022 Budget Request to Focus on COVID-19 R&D, Quality Generic System
August 20, 2021
- Japan Panel OKs COVID-19 Vaccine Health Damage Claims for First Time
August 20, 2021
- Japan Secures Enough Doses for Booster Shots Next Year: Minister
August 18, 2021
- Public-Private Dialogue for New Pharma Vision Set for Aug. 24
August 18, 2021
- Otsuka’s Eczema Med, Alexion’s Blood Thinner Antidote Up for PAFSC Review on Aug. 30
August 17, 2021
- 14 Firms Flock to Get Approval for E Keppra Generics towards December Listing
August 17, 2021
- MHLW OKs Ronapreve Use in Short-Term Hospitalization and at Accommodation Facilities
August 17, 2021
- Kono Says Vaccine Rollout Sped Up as Japan Hits 100 Million Dose Mark
August 11, 2021
- Japan to Run Follow-Up Survey for AstraZeneca Vaccine at 6 Hospitals
August 11, 2021
- Prefectural Governors Urge Booster Shot with AstraZeneca Jabs
August 11, 2021
- Lawmakers See No Ultimate Goal in New Pharma Industry Vision
August 6, 2021
- No Major Safety Concerns for Moderna, Pfizer COVID-19 Vaccines: MHLW
August 6, 2021
- Results of Guidelines-Related Studies Can Be Used in Public Knowledge-Based Filings for Fertility Treatments: MHLW
August 6, 2021
- Veklury Distribution via Govt Purchase to Continue for Now: MHLW
August 6, 2021
- Council OKs Public Knowledge-Based Filing for New Indication for Fibrinogen
August 6, 2021
- Industry Sees Overhaul of CEA Scheme “Too Early,” Chuikyo Reps Agree
August 5, 2021
- Chuikyo Calls for Balanced Price-Setting for “Specific-Use” Drugs, Sakigake Products
August 5, 2021
- Ofev Faces 10%-Plus Cut in Quarterly Price Review; Veklury Gets Listing but No Copay for Now
August 5, 2021
- Chuikyo to Compile Proposal on SaMD Reimbursement by Year-End
August 5, 2021
- Up to 580,000 Doses of AstraZeneca’s COVID Vaccine to Be Distributed in Tokyo
August 5, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…